# Surrozen Inc. (SRZN)

Source: https://www.quantisnow.com/company/SRZN
Generated: 2026-11-21T10:38:15.206Z

- Ticker: SRZN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- SEC CIK: 0001824893
- Website: surrozen.com

## About

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.

## Latest SRZN news and filings

- 2026-11-20 21:49 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-surrozen-inc-6802504)
- 2026-11-18 23:58 UTC [SEC Schedule 13D] [Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-surrozen-inc-6799500)
- 2026-11-18 21:41 UTC [SEC Form S-3] [SEC Form S-3 filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-surrozen-inc-6799128)
- 2026-11-17 00:04 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-surrozen-inc-6795156)
- 2026-11-16 21:43 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-surrozen-inc-6794708)
- 2026-11-16 15:02 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-surrozen-inc-6793012)
- 2026-11-16 13:25 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-surrozen-inc-6792526)
- 2026-11-16 13:11 UTC [SEC Form 8-K] [Surrozen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/surrozen-inc-filed-sec-form-8-k-entry-into-a-material-6792477)
- 2026-11-16 11:10 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-surrozen-inc-6791988)
- 2026-11-13 22:35 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-surrozen-inc-6791565)
- 2026-11-13 13:04 UTC [SEC Form FWP] [SEC Form FWP filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-surrozen-inc-6789471)
- 2026-11-13 13:00 UTC [Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock](https://www.quantisnow.com/insight/surrozen-announces-pricing-of-60-million-underwritten-offering-of-common-6789440)
- 2026-11-09 21:59 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-surrozen-inc-6781919)
- 2026-11-09 21:18 UTC [SEC Form 8-K] [Surrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/surrozen-inc-filed-sec-form-8-k-results-of-operations-and-6781548)
- 2026-11-09 21:05 UTC [Earnings] [Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/surrozen-reports-third-quarter-2026-financial-results-and-provides-business-6781148)
- 2026-11-06 21:40 UTC [Conference Announcement] [Surrozen to Present at Upcoming Healthcare Investor Conference](https://www.quantisnow.com/insight/surrozen-to-present-at-upcoming-healthcare-investor-conference-6779321)
- 2026-11-06 21:12 UTC [SEC Schedule 13D] [Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-surrozen-inc-6778990)
- 2026-10-22 20:48 UTC [SEC Form 4] [SEC Form 4 filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-surrozen-inc-6755439)
- 2026-10-22 20:45 UTC [SEC Form 4] [SEC Form 4 filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-surrozen-inc-6755432)
- 2026-10-22 20:45 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-surrozen-inc-6755431)
- 2026-10-20 21:04 UTC [SEC Form 8-K] [SEC Form 8-K filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-surrozen-inc-6752420)
- 2026-10-20 20:59 UTC [Public Offering] [Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million](https://www.quantisnow.com/insight/surrozen-announces-closing-of-second-tranche-of-march-2025-private-6752383)
- 2026-10-02 12:05 UTC [SEC Form 8-K] [Surrozen Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/surrozen-inc-filed-sec-form-8-k-other-events-6733518)
- 2026-10-02 12:00 UTC [Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema](https://www.quantisnow.com/insight/surrozen-announces-fda-clearance-of-ind-application-for-szn-8141-for-6733476)
- 2026-09-08 12:30 UTC [Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema](https://www.quantisnow.com/insight/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-6707641)
- 2026-09-02 20:05 UTC [Conference Announcement] [Surrozen to Present at Upcoming Healthcare Investor Conferences](https://www.quantisnow.com/insight/surrozen-to-present-at-upcoming-healthcare-investor-conferences-6703059)
- 2026-08-20 12:37 UTC [Analyst Coverage Initiated] [William Blair initiated coverage on Surrozen with a new price target](https://www.quantisnow.com/insight/william-blair-initiated-coverage-on-surrozen-with-a-new-price-6689598)
- 2026-08-07 21:03 UTC [SEC Form 25-NSE filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-surrozen-inc-6672061)
- 2026-08-06 20:23 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Surrozen Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-surrozen-inc-6669446)
- 2026-08-06 20:15 UTC [SEC Form 8-K] [Surrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/surrozen-inc-filed-sec-form-8-k-results-of-operations-and-6669274)
- 2026-08-06 20:05 UTC [Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/surrozen-reports-second-quarter-2026-financial-results-and-provides-business-6668765)
- 2026-07-25 01:00 UTC [SEC Form 4] [Large owner Tcg Crossover Gp Ii, Llc sold $6,906,250 worth of shares (325,000 units at $21.25) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-tcg-crossover-gp-ii-llc-sold-6906250-worth-6648739)
- 2026-07-15 20:05 UTC [Conference Announcement] [Surrozen to Present at Upcoming Healthcare Investor Conference](https://www.quantisnow.com/insight/surrozen-to-present-at-upcoming-healthcare-investor-conference-6638209)
- 2026-06-16 20:55 UTC [SEC Form 4] [Chief Financial Officer Maleki Andrew Pedrum was granted 607 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-maleki-andrew-pedrum-was-granted-607-shares-6605174)
- 2026-06-16 20:51 UTC [SEC Form 4] [Exec. Vice President, Research Li Yang was granted 1,666 shares, increasing direct ownership by 10% to 18,882 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-vice-president-research-li-yang-was-granted-1666-shares-6605146)
- 2026-06-16 20:47 UTC [SEC Form 4] [Chief Operating Officer Williams Charles O was granted 1,666 shares, increasing direct ownership by 10% to 18,237 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-williams-charles-o-was-granted-1666-shares-6605116)
- 2026-06-16 20:44 UTC [SEC Form 4] [Chief Executive Officer Parker Craig C was granted 1,622 shares, increasing direct ownership by 10% to 18,175 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-parker-craig-c-was-granted-1622-shares-6605092)
- 2026-05-19 20:41 UTC [SEC Form 4] [SEC Form 4 filed by Director Kutzkey Tim](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kutzkey-tim-6563101)
- 2026-05-18 10:49 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-surrozen-inc-6559003)
- 2026-05-15 20:37 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-surrozen-inc-6557960)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SRZN
- Earnings history: https://www.quantisnow.com/earnings/SRZN
- Dividend history: https://www.quantisnow.com/dividends/SRZN
- Insider transactions: https://www.quantisnow.com/insiders/SRZN
- Options chain: https://www.quantisnow.com/options/SRZN
- SEC 8-K filings only: https://www.quantisnow.com/company/SRZN/8-k
- RSS and alerts for SRZN: https://www.quantisnow.com/docs/rss-feeds.md
